A Study of JNJ-1761981 in Participants With Solid Tumors
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
| Condition(s) | Neoplasms |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions. |
| Who can participate | Inclusion criteria: * Part 1: Individuals with a diagnosis of locally advanced or metastatic disease (solid tumors except tumors of the central nervous system \[CNS\]) who have previously received available standard therapy and progressed, or cannot tolerate standard therapy, or for whom there is no standard of care per regional guidelines * Part 2 Cohort A: Individuals with histologically or cytologically confirmed metastatic tumors of adenocarcinoma or squamous cell carcinoma histology, for which any platinum-based systemic regimen is considered a standard of care (per national comprehensive cancer network \[NCCN\] guidelines) and whose disease has progressed after standard therapy * Eastern cooperative oncology group performance status (ECOG) performance status of Grade 0 or 1 * Part 2 |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Johnson & Johnson Enterprise Innovation Inc. |
| Locations | The Bronx, New York, United States; Houston, Texas, United States |
| Start date | 2026-05-26 |
| NCT ID | NCT07525141 |
| Official listing | https://clinicaltrials.gov/study/NCT07525141 |